Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that decreases the amount of acid produced in the stomach. It is available in oral and intravenous formulations.
## Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Healing of duodenal ulcers
* Maintenance of healing of erosive esophagitis
* Treatment of GERD symptoms
* Part of *Helicobacter pylori* eradication regimens
## Adult Dosing
* **GERD/Erosive Esophagitis (Healing):** 40 mg orally or IV once daily for up to 8 weeks.
* **GERD/Erosive Esophagitis (Maintenance):** 40 mg orally once daily. Doses of 20 mg orally once daily may be sufficient for some patients.
* **Duodenal Ulcer (Healing):** 40 mg orally once daily for up to 4 weeks.
* ***H. pylori* Eradication:** 40 mg orally twice daily for 7-14 days in combination with antibiotics.
* **Zollinger-Ellison Syndrome:** Dosing varies widely. Start with 40 mg orally or IV once daily. Doses can be increased as needed. The maximum recommended daily dose is 240 mg IV or 120 mg orally divided every 12 hours.
## Pediatric Dosing
* **GERD/Erosive Esophagitis (12 years and older):** 40 mg orally once daily for up to 8 weeks.
* **GERD/Erosive Esophagitis (5 years to 11 years):** 20 mg orally once daily for up to 8 weeks.
* **GERD/Erosive Esophagitis (1 month to 5 years):** Dosing is less established and may vary. Consult specific pediatric guidelines or literature. Typical ranges for oral administration are 0.8 to 1.3 mg/kg/day divided once or twice daily, not to exceed 40 mg/day.
## Dose Adjustments
* **Hepatic Impairment:** For oral formulations, the maximum dose is 20 mg once daily. IV dosing may also require adjustment; consult specific product labeling.
* **Renal Impairment:** No dose adjustment is generally needed.
## Contraindications
* Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Serious: *Clostridium difficile*-associated diarrhea, bone fracture (hip, wrist, spine) with long-term use, hypomagnesemia (especially with prolonged use, >1 year), fundic gland polyps, potential for drug-induced lupus erythematosus.
## Key Drug Interactions
* **Antiretrovirals (e.g., rilpivirine, atazanavir):** Decreased absorption due to increased gastric pH. Avoid co-administration.
* **Methotrexate:** Increased methotrexate levels may occur, potentially leading to toxicity. Consider temporarily discontinuing pantoprazole.
* **CYP2C19 substrates (e.g., clopidogrel):** Pantoprazole may inhibit CYP2C19, potentially reducing the efficacy of clopidogrel. The clinical significance is debated; consider alternatives if significant risk.
* **Iron salts:** Decreased absorption due to increased gastric pH.
## Monitoring
* Electrolytes (especially magnesium, calcium, potassium) with prolonged therapy.
* Signs and symptoms of *Clostridium difficile* infection.
* Bone mineral density with long-term use.
* Renal function, especially if hypomagnesemia is suspected.
## Clinical Pearls
* Oral pantoprazole is generally recommended to be taken 30-60 minutes before a meal.
* IV administration should be given as a slow infusion over 15 minutes or longer.
* Long-term PPI use is associated with increased risks of fractures, *C. difficile* infection, and vitamin B12 deficiency. Reassess the need for therapy periodically.
* Discontinuation of PPIs should ideally be tapered to avoid rebound acid hypersecretion.
---
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions.*
